- Home
- FURY vs CGTX Comparison
FURY vs CGTX Comparison
Compare FURY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 94.5M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FURY | CGTX |
|---|---|---|
| Price | $0.77 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.40 | ★ $3.33 |
| AVG Volume (30 Days) | ★ 821.8K | 771.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.22 |
| 52 Week High | $1.02 | $3.83 |
Technical Indicators
Market Signals| Indicator | FURY | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 43.68 |
| Support Level | $0.60 | $0.98 |
| Resistance Level | $0.89 | $1.21 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 77.38 | 37.50 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.